Comparison of LecT-Hepa and FibroScan for assessment of liver fibrosis in hepati

StephenW

Clin Chim Acta. <http://www.ncbi.nlm.nih.gov/pubmed/22796373##> 2012 Jul 12. [Epub ahead of print]

Comparison of LecT-Hepa and FibroScan for assessment of liver fibrosis in hepatitis B virus infected patients with different ALT levels.

Du D
, Zhu X
, Kuno A
, Matsuda A
, Tsuruno C
, Yu D
, Zhang Y
, Ikehara Y
, Tanaka Y
, Zhang X
, Narimatsu H
.

Sourcehttp://www.ncbi.nlm.nih.gov/pubmed/22796373

Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197, Ruijin Er Road, Shanghai 200025, China; Research Center for Medical Glycoscience (RCMG), National Institute of Advanced Industrial Science and Technology (AIST), 1-1-1 Umezono, Tsukuba, Ibaraki 305-8568, Japan; SCSB (China) - AIST (Japan) Joint Medical Glycomics Laboratory, 800 Dong Chuan Road, Minhang, Shanghai 200240, China.

Abstract

BACKGROUND:

FibroScan is one of the noninvasive techniques based on the transient elastography that can assess the progression of liver fibrosis in chronic hepatitis patients in daily clinical practice. Recently, LecT-Hepa was validated as a serological glycomarker correlating well with the fibrosis stage determined by liver biopsy, and was superior to many other noninvasive biochemical markers and tests. We compared the reliability of LecT-Hepa with that of FibroScan for evaluation of liver fibrosis.

METHODS:

The effects of increased alanine aminotransferase (ALT) activities on LecT-Hepa and FibroScan were investigated.

RESULTS:

The areas under the receiver-operating characteristic curves, sensitivity and specificity for detecting cirrhosis, which is one of the outcomes of fibrosis estimation, were 0.82 , 72.5% and 78.2% of LecT-Hepa, 0.85, 87.0% and 74.1% of FibroScan; these did not differ significantly. The count distribution of LecT-Hepa in non-cirrhosis group or cirrhosis group did not differ between the patients grouped according to their ALT levels, whereas that of FibroScan was substantially affected.

CONCLUSION:

LecT-Hepa was confirmed as a reliable noninvasive test for the evaluation of liver fibrosis in hepatitis B virus-infected patients with comparable performance to that of FibroScan and proved to be unaffected by inflammation.

StephenW

临床詹文献。 <http://www.ncbi.nlm.nih.gov/pubmed/22796373##&gt; 2012 7月12日。 [出处提前打印]

LECT-HEPA比较，FibroScan肝纤维化的评估，在B型肝炎病毒感染的患者ALT水平不同。

杜ð，朱
，久野一
，松田一
，鹤野Ç
，俞ð

，IkeharaŸ
，田中Ÿ
，张
，NarimatsuĤ

sourcehttp :/ / www.ncbi.nlm.nih.gov/pubmed/22796373

部传染病，瑞金医院，上海交通大学医学院，197号，瑞金二路，上海200025，中国医学糖科学的研究中心（RCMG），国家先进工业科学和技术研究所（AIST），1  - 1-1 Umezono，筑波市，茨城县305-8568，日本;的SCSB（中国） - 上海市闵行区东川路800号，联合医疗糖组学实验室，上海200240，中国综合研究所（日本）。

抽象

背景：

FibroScan是基于瞬时弹性，可以在日常临床实践中的慢性肝炎患者肝纤维化的进展评估的非侵入性技术之一。近日，LECT-HEPA验证以及肝活检确定纤维化分期与血清学的相关glycomarker，是优于其他许多非侵入性的生化指标和测试。我们比较了肝纤维化的评价FibroScan LECT-HEPA的可靠性。

方法：

增加丙氨酸转氨酶（ALT）LECT-HEPA和FibroScan活动的影响进行了调查。

结果：

根据接收机操作特性曲线，灵敏度和特异性检测肝硬化，其中是纤维化估计的成果之一，面积分别为0.82，72.5％和78.2％LECT-HEPA，0.85，87.0％和74.1％FibroScan;这些并没有显著差异。 LECT-HEPA计数分布在非肝硬化组或肝硬化组分组根据自己的ALT水平，而FibroScan，严重影响患者之间没有差别。

结论：

LECT-HEPA被证实在B型肝炎病毒感染的患者具有同等性能的FibroScan作为一个可靠的评价肝纤维化的无创性测试，并证明是炎症的影响。